Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sunovion’s Bipolar Depression Med Fails to Show Statistically Significant Improvement in PII
July 8, 2020
- Keytruda Snatches Back Top Crown in June Drug Sales Ranking: Encise
July 7, 2020
- Amgen Takes Over Japan MA for Otezla
July 7, 2020
- Eisai Launches Dayvigo, Fycompa Fine Granules in Japan
July 7, 2020
- Ono to Fight Prof. Honjo’s Lawsuit over Opdivo Royalties
July 7, 2020
- Chugai Aspires to Become World Top Innovator Post-COVID-19 Era: President
July 7, 2020
- Maviret Shrivels, but AbbVie Japan in “Growth Mode” with Oncology, Immunology Drivers: Chief
July 3, 2020
- GSK Japan Sets Up Women’s Leadership Initiative to Bring Diversity in Managerial Ranks
July 3, 2020
- Daiichi Sankyo Adds Patients with Triple Negative Breast Cancer into PI DS-1062 Study
July 3, 2020
- Nobelpharma Launches European Subsidiary in Germany
July 3, 2020
- Fujifilm Inks Global Avigan Deal with Dr. Reddy’s, Global Response Aid
July 2, 2020
- Nippon Shinyaku, Torii to Invest in New Biotech Funds
July 2, 2020
- Tolerability of Telomelysin for HCC Confirmed in PI: Oncolys
July 2, 2020
- Eisai’s Eritoran to Enter Clinical Study for COVID-19 on Global Platform
July 2, 2020
- Towa Comarkets Celltrion’s Remicade Biosimilar in Japan
July 2, 2020
- Aspen Japan to Take Over Anti-Anxiety Med Lexotan
July 2, 2020
- AstraZeneca Taps Celgene Exec as New R&D Head
July 2, 2020
- 26 Japan Drug Makers Log 4% Fall in Workforce as Downtrend Continues Unabated: FY2019 Securities Reports
July 1, 2020
- Rakuten Medical’s Photoimmunotherapy Filed in Japan, Subject to Conditional Early OK
July 1, 2020
- Shionogi, StemRIM Extend Collaboration for “Regeneration-Inducing Medicine”
July 1, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…